Dianthus Therapeutics, Inc. DNTH R2K
Healthcare · Biotechnology · United States
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
READ MORE ›$93.01
+434.85% 1Y
Market & Price
Market Cap
$5.08B
Current Price
$93.01
High / Low (52W)
$95.76 / $16.86
Beta
0.09
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$22.01
Price to Book
4.23
P/S
3,805.77
EV/EBITDA
-20.79
Dividend Yield
-
Profitability & Returns
ROCE
-35.57%
ROE
-22.70%
ROA
-14.99%
Profit Margin
0.00%
Op Margin
-
EPS (Latest Qtr)
$-0.85
EPS (TTM)
$-4.23
Balance Sheet & Liquidity
Debt/Equity
0.11
Quick Ratio
29.06
Current Ratio
29.25
Debt
$1.36M
Total Assets
$530.92M
Current Assets
$409.44M
Working Capital
$378.71M
Ownership
Promoter Holding
0.13%
Chg in Prom Hold
-
FII / Inst Holding
120.31%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$3.97B
Total Revenue (TTM)
$1.34M
EBITDA
$-191.17M
Free Cash Flow
$-71.03M
Operating Cash Flow
$-130.29M
Shares Outstanding
54.67M
Gross Margin
100.00%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
-31.80%
Profit 5Y
-156.69%
Revenue (YoY)
-60.20%
Earnings (YoY)
-
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -31.8% CAGR over 5 years.
- Earnings shrank at -156.7% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DNTH Dianthus Therapeutics, Inc. R2K | 93.01 | - | $5.08B | - | -35.57% | -22.70% | -31.80% | -156.69% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.17M | - | - | 924.00K | 874.00K | 1.86M | 2.17M | 1.16M | 193.00K | 396.00K | 284.00K | 463.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 34.34M | 35.12M | 40.68M | 69.83M | 47.00M |
| Operating Income | -4.81M | -15.73M | -7.01M | -8.17M | -11.31M | -14.03M | -16.70M | -17.93M | -16.35M | -19.34M | -22.64M | -24.64M | -21.24M | -20.01M | -18.38M | -18.70M | -17.61M | -18.25M | -23.83M | -18.08M | -8.25M | -7.68M | -11.78M | -15.76M | -17.84M | -22.20M | -29.90M | -33.18M | -34.93M | -40.29M | -69.54M | -46.53M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -33.04M | -34.83M | -40.19M | -69.44M | -46.46M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -29.51M | -31.63M | -36.77M | -64.43M | -40.83M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -4.81M | -15.73M | -6.91M | -8.04M | -11.16M | -13.66M | -16.02M | -16.68M | -14.83M | -17.71M | -20.99M | -23.24M | -20.01M | -19.08M | -17.68M | -17.49M | -16.93M | -17.43M | -4.88M | -5.70M | -7.78M | -7.09M | -11.14M | -14.76M | -13.75M | -17.61M | -25.17M | -29.51M | -31.63M | -36.77M | -64.43M | -40.83M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.36 | -0.32 | -0.30 | -0.39 | -0.29 | -8.90 | -8.10 | -12.73 | -3.78 | -0.54 | -0.51 | -0.74 | -0.82 | -0.88 | -0.97 | -1.43 | -0.85 |
| R&D Expense | - | 13.82M | 5.21M | - | 7.85M | 9.68M | 11.42M | - | 10.54M | 13.43M | 16.52M | - | 13.96M | 12.61M | 11.79M | 11.73M | 11.13M | 10.79M | 16.55M | 11.60M | 7.22M | 5.85M | 10.25M | 7.96M | 13.08M | 18.07M | 25.54M | 27.00M | 26.25M | 32.49M | - | 34.53M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 6.42M | 2.83M | 6.24M | 2.04M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | 36.12M | 51.00M | 108.10M | 179.97M |
| Operating Income | -9.27M | -35.73M | -59.96M | -82.97M | -78.70M | - | -29.70M | -48.17M | -101.86M | -177.93M |
| EBITDA | - | - | - | - | - | - | -29.56M | -47.82M | -101.45M | -177.50M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | -28.48M | -43.55M | -84.97M | -162.34M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - |
| Net Income | -9.43M | -35.49M | -57.52M | -76.77M | -74.94M | - | -28.48M | -43.55M | -84.97M | -162.34M |
| Diluted EPS | - | - | - | - | -1.71 | -0.88 | -1.92 | -8.45 | -2.55 | - |
| R&D Expense | 5.78M | 27.90M | 41.34M | 59.21M | 50.62M | 46.77M | 29.38M | 32.84M | 83.11M | 145.64M |
Compounded Sales Growth
| 5 Years: | -31.80% |
| 1 Year: | -60.20% |
Compounded Profit Growth
| 5 Years: | -156.69% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +434.85% |
| 6 Months: | +110.95% |
| 3 Months: | +68.53% |
| 1 Month: | +11.39% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 54.46M | 157.31M | 161.51M | 161.62M | - | 83.11M | 179.41M | 374.01M | 530.92M |
| Current Assets | - | - | - | - | - | - | - | 82.03M | 177.45M | 280.90M | 409.44M |
| Cash & Equivalents | - | - | 51.40M | 58.34M | 65.07M | 58.15M | - | 15.37M | 132.32M | 22.79M | 51.09M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | 0 | 52.00K |
| Total Liabilities | - | - | 4.14M | 11.66M | 20.32M | 17.71M | - | 9.45M | 10.54M | 21.53M | 37.52M |
| Current Liabilities | - | - | 4.14M | 10.42M | 14.12M | 11.43M | - | 8.22M | 9.63M | 18.45M | 30.73M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | 788.00K | 585.00K | 1.49M | 1.39M |
| Total Equity | -289.00K | -8.87M | -42.12M | 145.65M | 141.19M | 143.91M | - | 73.66M | 168.87M | 352.48M | 493.40M |
| Shares Outstanding | - | - | - | - | - | - | - | 14.82M | 14.82M | 31.12M | 43.22M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -6.53M | -22.26M | -41.89M | -57.10M | -64.02M | - | -29.07M | -36.86M | -78.18M | -129.06M |
| Investing Cash Flow | -139.00K | -2.20M | -91.70M | 1.53M | -10.63M | - | -59.82M | 20.25M | -286.81M | -122.83M |
| Financing Cash Flow | 10.71M | 71.49M | 142.15M | 62.30M | 67.74M | - | 96.68M | 133.57M | 255.62M | 280.12M |
| Capital Expenditure | -139.00K | -2.20M | -7.67M | -3.06M | -400.00K | - | -139.00K | -110.00K | -105.00K | -213.00K |
| Free Cash Flow | -6.67M | -24.46M | -49.56M | -60.16M | -64.42M | - | -29.21M | -36.97M | -78.28M | -129.27M |
| Net Change in Cash | - | - | - | - | - | - | 7.79M | 116.97M | -109.37M | 28.23M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | -462.9% | -1,704.7% | -1,633.7% | -8,739.3% |
| Net Margin % | - | - | - | - | - | - | -443.8% | -1,541.2% | -1,362.8% | -7,973.3% |
| ROE % | 106.3% | 84.3% | -39.5% | -54.4% | -52.1% | - | -38.7% | -25.8% | -24.1% | -32.9% |
| ROCE % | - | -71.0% | -40.8% | -56.3% | -52.4% | - | -39.7% | -28.4% | -28.6% | -35.6% |
Shareholding Pattern
Insiders
0.13%
Institutions
120.31%
Public Float
120.46%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 14.21% | 7.77M | $722.47M |
| 2 | Blackrock Inc. | 5.81% | 3.18M | $295.37M |
| 3 | RA Capital Management, L.P. | 4.78% | 2.61M | $242.92M |
| 4 | Wellington Management Group, LLP | 4.75% | 2.60M | $241.43M |
| 5 | Fairmount Funds Management LLC | 4.64% | 2.54M | $235.98M |
| 6 | Avidity Partners Management, LP | 3.85% | 2.10M | $195.71M |
| 7 | Vanguard Capital Management LLC | 3.72% | 2.03M | $188.93M |
| 8 | Octagon Capital Advisors LP | 3.56% | 1.95M | $181.06M |
| 9 | TCG Crossover Management, LLC | 3.07% | 1.68M | $155.94M |
| 10 | Citadel Advisors Llc | 2.95% | 1.61M | $149.79M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DNTH
No recent headlines available.